Genmab loses royalties case against Janssen

In two seperate issues concerning royalty payments related to Genmab’s drug Darzalex, a tribunal in the US has ruled in favor of Janssen. (Updated)

Photo: Joost Melis / Genmab / PR

Three arbitrators have ruled in Janssen’s favor in a dispute with Genmab over royalties payments.

There were two points of contention in the case, which was brought after the launch of a faster version of Darzalex, Darzalex Faspro.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs